Company newsForm 8-K
AbCellera Biologics ABCL
AbCellera Biologics shareholders elect two Class III directors
The meeting covered 305,264,947 common shares outstanding and entitled to vote as of the April 15, 2026 record date.
GetSignal
AbCellera Biologics shareholders elected John S. Montalbano, CFA, and Stephen R. Quake, D.Phil., as Class III directors at the annual meeting held June 11, 2026, for three-year terms expiring at the 2029 annual meeting.
Shareholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved named executive compensation on a non-binding advisory basis.
Key facts
- Meeting date
- June 11, 2026
- Montalbano votes
- 141,430,732 for, 12,723,342 against, 45,898 abstain
- Quake votes
- 149,019,960 for, 5,113,056 against, 66,956 abstain
Source: Form 8-K filed June 12, 2026.
Written by GetSignal with AI from the company's SEC filing. How we make news
Not investment advice.
More company news
AbCellera Biologics first, then the newest- AbCellera Biologics prices $200 million offering of common shares and pre-funded warrants
ABCL · AbCellera Biologics · Form 8-K · Aug 13, 2026
- AbCellera Biologics appoints Lynn Seely to its board of directors
ABCL · AbCellera Biologics · Form 8-K · Jul 6, 2026
- Western Digital stockholders elect nine directors at annual meeting
WDC · Western Digital · Form 8-K · Nov 20, 2026
- Ares Capital subsidiary amends BNP Paribas funding facility
ARCC · Ares Capital · Form 8-K · Nov 20, 2026
